Moshe Elkabets

mTORC1 Inhibition Is Required for Sensitivity to PI3K p110α Inhibitors in <i>PIK3CA</i> -Mutant Breast Cancer

Moshe Elkabets, Sadhna Vora, Dejan Juric et al. · Science Translational Medicine · 2013 · 344 citations · Full text

AXL Mediates Resistance to PI3Kα Inhibition by Activating the EGFR/PKC/mTOR Axis in Head and Neck and Esophageal Squamous Cell Carcinomas

Moshe Elkabets, Evangelos Pazarentzos, Dejan Juric et al. · Cancer Cell · 2015 · 331 citations · Full text

Oncology, Pi3kα Inhibition, Signaling Pathway +13

IL‐1β regulates a novel myeloid‐derived suppressor cell subset that impairs NK cell development and function

Moshe Elkabets, Vera S. G. Ribeiro, Charles A. Dinarello et al. · European Journal of Immunology · 2010 · 309 citations · Full text

Lymphocyte Development, Immunology, Immune Regulation +20

Interleukin-1β–Driven Inflammation Promotes the Development and Invasiveness of Chemical Carcinogen–Induced Tumors

Yakov Krelin, Elena Voronov, Shahar Dotan et al. · Cancer Research · 2007 · 271 citations · Full text

PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D

Eneda Toska, Hatice U. Osmanbeyoglu, Pau Castel et al. · Science · 2017 · 260 citations · Full text